Orchard Therapeutics plc
ORTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $47 | $164 | $430 | $1,282 |
| - Cash | $68 | $56 | $55 | $19 |
| + Debt | $58 | $59 | $58 | $46 |
| Enterprise Value | $37 | $167 | $433 | $1,309 |
| Revenue | $7 | $0 | $3 | $3 |
| % Growth | 1,346.4% | -81.4% | 3.3% | – |
| Gross Profit | $5 | $0 | $2 | $2 |
| % Margin | 65.2% | 53.2% | 67% | 68% |
| EBITDA | -$8 | -$36 | -$148 | -$155 |
| % Margin | -115.6% | -7,358.4% | -5,717.8% | -6,182.8% |
| Net Income | -$8 | -$36 | -$152 | -$163 |
| % Margin | -112.8% | -7,525.7% | -5,856.6% | -6,503.1% |
| EPS Diluted | -0.61 | -2.93 | -15.28 | -17.53 |
| % Growth | 79.2% | 80.8% | 12.8% | – |
| Operating Cash Flow | -$76 | -$125 | -$126 | -$166 |
| Capital Expenditures | -$7 | -$3 | -$13 | -$4 |
| Free Cash Flow | -$83 | -$128 | -$139 | -$170 |